Next-generation weight loss pills are expected to hit the market next year, and drugmakers are working on medications with ...
The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery.
Eli Lilly and Co. on Friday, Nov. 21 became the first health care company to surpass a $1 trillion market valuation, driven ...
In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.
Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...
Novo Nordisk is also currently awaiting a decision from the FDA, having previously applied for approval of its Wegovy weight-loss pill. As part of the U.S. pricing deal with the administration earlier ...
And one of them is pharmaceutical giant Pfizer ( PFE 0.04%). Now, with a major step along the path to entering this ...
Investors in Danish pharmaceutical leader Novo Nordisk experienced significant market volatility this week following ...
Inflammatory bowel disease (IBD) has expanded beyond its initial confines of early industrialised countries in North America, Europe, and Oceania and now constitutes a global illness. Once rare in the ...
Most people who stopped taking their weight loss injections also experienced negative changes in blood pressure, waist size, ...
In a groundbreaking class action, Wisner Baum LLP is invoking the civil RICO statute to hold Takeda and Eli Lilly accountable for allegedly concealing the cancer risks of diabetes drug Actos. The case ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback